190 related articles for article (PubMed ID: 32796162)
1. Prevention of adverse drug effects: a pharmacogenomic approach.
Scott EN; Hasbullah JS; Carleton BC; Ross CJD
Curr Opin Pediatr; 2020 Oct; 32(5):646-653. PubMed ID: 32796162
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy.
Loucks CM; Yan K; Tanoshima R; Ross CJD; Rassekh SR; Carleton BC
Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1():95-99. PubMed ID: 33900042
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A; Conyers R; Elliott DA
Clin Pharmacol Ther; 2019 Mar; 105(3):614-624. PubMed ID: 30460992
[TBL] [Abstract][Full Text] [Related]
4. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.
Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh SR; Ross C; Carleton B
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29271558
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Barhdadi A; Dubé MP; Al-Saloos H; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Brown AM; Rogers PC; Phillips MS; Rieder MJ; Carleton BC; Hayden MR;
J Clin Oncol; 2012 May; 30(13):1422-8. PubMed ID: 21900104
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
8. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care.
Chenchula S; Atal S; Uppugunduri CRS
Pharmacogenomics J; 2024 Mar; 24(2):9. PubMed ID: 38490995
[TBL] [Abstract][Full Text] [Related]
9. A review of pharmacogenetics of adverse drug reactions in elderly people.
Cardelli M; Marchegiani F; Corsonello A; Lattanzio F; Provinciali M
Drug Saf; 2012 Jan; 35 Suppl 1():3-20. PubMed ID: 23446782
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Adverse Drug Reactions.
Osanlou O; Pirmohamed M; Daly AK
Adv Pharmacol; 2018; 83():155-190. PubMed ID: 29801574
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-related cardiotoxicity: are Australian practitioners missing the point?
Conyers R; Costello B; La Gerche A; Tripaydonis A; Burns C; Ludlow L; Lange P; Ekert P; Mechinaud F; Cheung M; Martin M; Elliot D
Intern Med J; 2017 Oct; 47(10):1166-1172. PubMed ID: 28485067
[TBL] [Abstract][Full Text] [Related]
12. The role of pharmacogenomics in adverse drug reactions.
Cacabelos R; Cacabelos N; Carril JC
Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
[TBL] [Abstract][Full Text] [Related]
13. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
Mhandire DZ; Goey AKL
Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.
Visscher H; Amstutz U; Sistonen J; Ross CJ; Hayden MR; Carleton BC
J Cardiovasc Pharmacol; 2011 Sep; 58(3):228-39. PubMed ID: 21386709
[TBL] [Abstract][Full Text] [Related]
15. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.
Visscher H; Ross CJ; Rassekh SR; Sandor GS; Caron HN; van Dalen EC; Kremer LC; van der Pal HJ; Rogers PC; Rieder MJ; Carleton BC; Hayden MR;
Pediatr Blood Cancer; 2013 Aug; 60(8):1375-81. PubMed ID: 23441093
[TBL] [Abstract][Full Text] [Related]
16. Reducing anthracycline-induced cardiotoxicity through pharmacogenetics.
Scott E; Hasbullah JS; Ross CJ; Carleton BC
Pharmacogenomics; 2018 Oct; 19(15):1147-1150. PubMed ID: 30213233
[No Abstract] [Full Text] [Related]
17. [Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions].
Mushiroda T
Nihon Yakurigaku Zasshi; 2024; 159(2):90-95. PubMed ID: 38432925
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacogenetics and prediction of side effects of drugs].
Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
[TBL] [Abstract][Full Text] [Related]
19. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.
Meiners B; Shenoy C; Zordoky BN
Biol Sex Differ; 2018 Aug; 9(1):38. PubMed ID: 30157941
[TBL] [Abstract][Full Text] [Related]
20. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
